Results of the double-blind phase 3 CELESTIAL study, presented at the 2018 Gastrointestinal Cancers Symposium, demonstrated efficacy of cabozantinib in patients with HCC who were previously treated with sorafenib.
In a phase 3 study presented at the 2018 Gastrointestinal Cancers Symposium, researchers reported on OS outcomes with gemcitabine plus S-1 vs gemcitabine plus cisplatin in patients with advanced biliary tract cancer.
The FDA based its approval on data collected from the open-label, phase 2 CABOSUN study, for which researchers randomly assigned 157 patients with RCC to receive oral cabozantinib or sunitinib.
Recent studies have suggested that married patients experience a survival benefit for various cancers; marriage has been associated with earlier detection, undergoing treatment, as well as better economic status and social support.
Optimal Therapy for Patients with Hepatocellular Carcinoma and Resistance or Intolerance to Sorafenib: Challenges and SolutionsDecember 08, 2017
[Journal of Hepatocellular Carcinoma] This research examines systemic therapies that can be considered in patients with sorafenib refractory hepatocellular carcinoma.
This case describes management of a 61-year-old male with a history of chronic liver diseases and COPD who developed a posttransplant lymphoproliferative disorder 10 years after a liver transplant.
Study presented at the AASLD The Liver Meeting 2017 demonstrated the effect of regular aspirin use on risk of hepatocellular carcinoma in patients with chronic HBV.
Reducing the initial dose of sorafenib was shown to have some benefits — such as reduced pill burden, lower costs, and decreased AE-related discontinuation rates — and OS was noninferior compared with the standard dose in patients with hepatocellular carcinoma.
Hispanic race and insurance coverage associated with lower referral to palliative care, data indicates.
A new report from ACS describes trends in liver cancer and the factors influencing the ongoing increase in incidence, particularly higher rates of HCV infection, obesity, and type 2 diabetes.
Liver cancer mortality has increased at a faster pace than other cancers in the United States, but substantial disparities exists in mortality rates for race/ethnicity and state of residence.
New data presented at the International Liver Congress 2017 suggest that nivolumab may produce long-term benefits in sorafenib-experienced patients with advanced HCC.
Decreased liver tumor growth and improved survival in a mouse model were noted after injecting iPS-ML/IFN-β.
[Journal of Hepatocellular Carcinoma] This research examines the outcomes of HCC patients with BDTT in a single institution.
This study examines the influences of liver enzymes on the overall survival in a number of patients with intrahepatic cholangiocarcinoma (ICC).
Treatment with cabozantinib was active and associated with manageable toxicities in patients with hepatocellular carcinoma.
[Journal of Hepatocellular Carcinoma] This research examines the medical challenges presented by pediatric hepatocellular carcinoma (HCC).
Profile of Tivantinib and its Potential in the Treatment of Hepatocellular Carcinoma: The Evidence to DateDecember 08, 2016
[Journal of Hepatocellular Carcinoma] This research examines tivantinib and its therapeutic profile in the management of hepatocellular carcinoma.
Prognostic role of pretreatment serum albumin in renal cell carcinoma: a systematic review and meta-analysisNovember 24, 2016
[OncoTargets and Therapy] This research examines the prognostic value of pretreatment serum albumin in RCC patients.
[Journal of Hepatocellular Carcinoma] This research examines the screening modalities, diagnosis, staging, and treatment of hepatocellular carcinoma (HCC), the most common primary liver malignancy.
Role of Regorafenib as Second-line Therapy and Landscape of Investigational Treatment Options in Advanced Hepatocellular CarcinomaOctober 27, 2016
[Journal of Hepatocellular Carcinoma] This review examines the multikinase inhibitors sorafenib and regorafenib, inhibitors of the MET pathway, and immunotherapeutics for the treatment of advanced hepatocellular carcinoma.
In patients with advanced HCC and a baseline αFP level of 400 ng/mL or more, a survival benefit with second-line ramucirumab therapy was observed for those with Child-Pugh scores of 5 and 6.
The multikinase inhibitor regorafenib significantly improved overall survival rates compared to placebo in patients with hepatocellular carcinoma, according to data from the phase 3 RESORCE trial.
Comparative Efficacy and Safety of Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-analysisJuly 07, 2016
[Oncotargets and Therapy] This research evaluates the comparative efficacy and safety of axitinib and sorafenib for the treatment of metastatic renal cell carcinoma.
Including an antiemetic in the preprocedure medications for patients with liver cancer undergoing drug eluting bead chemoembolization (DEB TACE) can shorten hospital stays and reduce the chance for readmission due to complications.
In patients with advanced hepatocellular carcinoma (HCC), adding doxorubicin to sorafenib did not improve overall survival or progression-free survival and resulted in higher toxicity compared to sorafenib alone, results from a phase 3 study presented at the ASCO 2016 Annual Meeting have shown.
A study of nearly 1000 patients with HCC found that black patients with the disease had a 33% greater risk of death compared with non-Hispanic whites.
Oncology nurses are in an ideal position to educate patients with gastrointestinal malignancies and PVT about risk factors, clinical presentation, complications, and treatment options to prevent further extension of the clot.
An interdisciplinary collaboration between prominent academic and industry investigators discovered a novel method for repositioning an FDA-approved anticancer compound so it can specifically target liver cancer tumors.
RNA test of blood platelets can detect, classify, and pinpoint the location of cancer by analyzing a sample equivalent to 1 drop of blood. Using this new method, researchers were able to identify cancer with 96% accuracy.
Sign Up for Free e-newsletters
- FDA Issues Warning for Rolapitant Injectable Emulsion in the Treatment of CINV
- Risk Factors for Arterial, Venous Thrombosis Differ in Polycythemia Vera
- Patient Satisfaction Ratings Can Be Negatively Impacted by Nurse Staffing Ratio
- Resolving Vaginal Dryness in Women With a History of Breast Cancer
- BRCA Mutation Improves Prognosis for 2-year Survival in Younger-onset TNBC
- Pertuzumab Regimen Approved for Adjuvant, Neoadjuvant Therapy in Specific Breast Cancers
- Common Oncologic Emergencies That Occur With Multiple Myeloma
- Artificial Sweeteners and Cancer Risk (Fact Sheet)
- Blueberry Extract May Boost Efficacy of Radiotherapy for Cervical Cancer
- Breast Implants Associated With Increased Risk of Breast Anaplastic Large-cell Lymphoma
- Partial Response Achieved With Atezolizumab, Cobimetinib in Pretreated CRC
- Novel Approach Can Improve Both Colorectal Cancer Screening Outcomes and Adherence
- Survival Outcomes in Relapsed Hepatocellular Carcinoma Improved With Cabozantinib
- OS Similar With Gemcitabine Plus S-1 vs Standard Therapy for Biliary Tract Cancer
- Feasibility and Outcomes of Modified Enhanced Recovery After Surgery for Nursing Management of Aged Patients Undergoing Esophagectomy
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|